NDAORALTABLET
Approved
Oct 2010
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
LATUDA (lurasidone hydrochloride) by Jubilant Therapeutics is unclear. Approved for schizophrenia, depression, schizophrenia. First approved in 2010.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LATUDA (lurasidone hydrochloride) is an oral atypical antipsychotic approved in 2010 for schizophrenia and bipolar depression. It works primarily through dopamine D2 and serotonin 5-HT2A receptor antagonism. The drug targets patients with serious mental illness who require dopaminergic modulation.
$0.227MPart D
Peak5.6 years to LOELATUDA operates in peak lifecycle with minimal Part D penetration ($227K annually), suggesting limited growth opportunity and potentially lean commercial teams focused on market defense.
Mechanism of Action
unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D 2 and serotonin Type 2 (5HT 2A ) receptor antagonism.
Indications (2)
Worked on LATUDA at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.